Biogen Inc., a global pharmaceutical manufacture, has launched a subsidiary global hemophilia business, Bioverativ.
Bioverativ is an independent, publicly traded company focused on hemophilia
and rare blood disorders.
The separation occurred on Feb. 1 with stock shares available for
purchase on Feb. 2. Biogen shareholders automatically received stock in
Bioverativ.
Biogen spins off Bioverativ with focus on hemophilia
Alerts Sign-up